Clinical Trial Update: A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating atezolizumab plus chemotherapy for patients with early relapsing recurrent triple-negative breast cancer has completed and posted resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Tecentriq (atezolizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Triple Negative Breast Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2025-11-12